Leap Therapeutics EBITDA vs. Shares Owned By Insiders
| LPTX Stock | USD 2.65 0.13 5.16% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -81 M | Current Value -76.9 M | Quarterly Volatility 23.3 M |
For Leap Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Leap Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Leap Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Leap Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Leap Therapeutics over time as well as its relative position and ranking within its peers.
Leap |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Leap Therapeutics. If investors know Leap will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Leap Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.003 | Return On Assets (0.46) | Return On Equity (0.81) |
The market value of Leap Therapeutics is measured differently than its book value, which is the value of Leap that is recorded on the company's balance sheet. Investors also form their own opinion of Leap Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Leap Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Leap Therapeutics' market value can be influenced by many factors that don't directly affect Leap Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Leap Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Leap Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Leap Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Leap Therapeutics Shares Owned By Insiders vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Leap Therapeutics's current stock value. Our valuation model uses many indicators to compare Leap Therapeutics value to that of its competitors to determine the firm's financial worth. Leap Therapeutics is rated below average in ebitda category among its peers. It is rated second overall in shares owned by insiders category among its peers . Leap Therapeutics reported EBITDA of (80.99 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Leap Therapeutics' earnings, one of the primary drivers of an investment's value.Leap Shares Owned By Insiders vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Leap Therapeutics |
| = | (80.99 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Leap Therapeutics |
| = | 17.28 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Leap Shares Owned By Insiders Comparison
Leap Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
Leap Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Leap Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Leap Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Leap Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Leap Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 106 K | 100.7 K | |
| Operating Income | -87 M | -82.7 M | |
| Income Before Tax | -81.4 M | -77.3 M | |
| Total Other Income Expense Net | 5.6 M | 5.9 M | |
| Net Loss | -81.4 M | -77.3 M | |
| Net Loss | -81.1 M | -77 M | |
| Net Loss | -49.1 M | -46.7 M | |
| Income Tax Expense | 132.3 K | 125.7 K | |
| Interest Income | 3.6 M | 3.8 M | |
| Net Interest Income | 3.6 M | 3.8 M | |
| Non Operating Income Net Other | -341.1 K | -324 K | |
| Change To Netincome | 7.1 M | 7.5 M | |
| Net Loss | (3.98) | (4.18) | |
| Income Quality | 0.54 | 0.92 | |
| Net Income Per E B T | 1.15 | 1.10 |
Leap Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Leap Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Leap Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Leap Therapeutics' important profitability drivers and their relationship over time.
Use Leap Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Leap Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Leap Therapeutics will appreciate offsetting losses from the drop in the long position's value.Leap Therapeutics Pair Trading
Leap Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Leap Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Leap Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Leap Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Leap Therapeutics to buy it.
The correlation of Leap Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Leap Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Leap Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Leap Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Leap Therapeutics position
In addition to having Leap Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Russia On Wall Street Thematic Idea Now
Russia On Wall Street
Cross-sector and cross-instrument bundle of publicly traded Russian entities that are expected to be listed on USA exchanges or over the counter. The Russia On Wall Street theme has 23 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Russia On Wall Street Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.